Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0MCVTG)
| ADC Name |
US11147852B2 5T4-L398C-L443C 1
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
5T4-L398C-L443C
Click to Show/Hide
|
|||||
| Organization |
PFIZER INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.8
|
|||||
| Antibody Name |
anti-5T4
|
Antibody Info | ||||
| Antigen Name |
Trophoblast glycoprotein (TPBG)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
McMMAD
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC56) | > 29000 ng/ml | Negative 5T4 expression (5T4-) | ||
| Method Description |
The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines
MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC56) | > 39000 ng/ml | Negative 5T4 expression (5T4-) | ||
| Method Description |
The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines
MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 79 ng/ml | Positive 5T4 expression (5T4+++/++) | ||
| Method Description |
The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines
MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
|
||||
| In Vitro Model | Amelanotic melanoma | MDA?MB?435 cells (5t4+) | CVCL_0417 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 81 ng/ml | Positive 5T4 expression (5T4+++/++) | ||
| Method Description |
The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines
MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
|
||||
| In Vitro Model | Amelanotic melanoma | MDA?MB?435 cells (5t4+) | CVCL_0417 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 5500 ng/ml | Positive 5T4 expression (5T4+++/++) | ||
| Method Description |
The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines
MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 7100 ng/ml | Positive 5T4 expression (5T4+++/++) | ||
| Method Description |
The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines
MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
References